Cyclo Therapeutics Enters into Note Purchase Agreement with Rafael HoldingsCyclo Therapeutics, Inc. (NASDAQ:CYTH) announced today that it has entered into a Sixth Amended and Restated Note Purchase Agreement with Rafael Holdings, Inc., a Delaware cor

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cyclo Therapeutics’s 8K filing here.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.